These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 22297501)

  • 1. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world.
    Frentz D; Boucher CA; van de Vijver DA
    AIDS Rev; 2012; 14(1):17-27. PubMed ID: 22297501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiology of antiretroviral drug resistance in drug-naïve persons.
    Geretti AM
    Curr Opin Infect Dis; 2007 Feb; 20(1):22-32. PubMed ID: 17197878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Geographic and temporal trends of transmitted HIV-1 drug resistance among antiretroviral-naïve subjects screening for two clinical trials in North America and Western Europe.
    Rahim S; Fredrick LM; da Silva BA; Bernstein B; King MS
    HIV Clin Trials; 2009; 10(2):94-103. PubMed ID: 19487179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral drug resistance--implications for HIV/AIDS reduction in sub-Saharan Africa and other developing countries.
    Obiako OR; Murktar HM; Ogoina D
    Niger J Med; 2010; 19(3):302-10. PubMed ID: 20845636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe.
    Pillay D
    Antivir Ther; 2004 Oct; 9(5):695-702. PubMed ID: 15535406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transmission of drug-resistant HIV-1 is stabilizing in Europe.
    Vercauteren J; Wensing AM; van de Vijver DA; Albert J; Balotta C; Hamouda O; Kücherer C; Struck D; Schmit JC; Asjö B; Bruckova M; Camacho RJ; Clotet B; Coughlan S; Grossman Z; Horban A; Korn K; Kostrikis L; Nielsen C; Paraskevis D; Poljak M; Puchhammer-Stöckl E; Riva C; Ruiz L; Salminen M; Schuurman R; Sonnerborg A; Stanekova D; Stanojevic M; Vandamme AM; Boucher CA
    J Infect Dis; 2009 Nov; 200(10):1503-8. PubMed ID: 19835478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population.
    Leigh Brown AJ; Frost SD; Mathews WC; Dawson K; Hellmann NS; Daar ES; Richman DD; Little SJ
    J Infect Dis; 2003 Feb; 187(4):683-6. PubMed ID: 12599087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral drug resistance--implications for HIV/AIDS reduction in sub-Saharan Africa and other developing countries.
    Obiako OR; Murktar HM; Ogoina D
    Niger J Med; 2010; 19(4):352-60. PubMed ID: 21526620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection.
    Menéndez-Arias L; Alvarez M
    Antiviral Res; 2014 Feb; 102():70-86. PubMed ID: 24345729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000.
    Scott P; Arnold E; Evans B; Pozniak A; Moyle G; Shahmenesh M; White D; Shirley J; Cane P; Pillay D
    J Antimicrob Chemother; 2004 Mar; 53(3):469-73. PubMed ID: 14749345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral-drug resistance among patients recently infected with HIV.
    Little SJ; Holte S; Routy JP; Daar ES; Markowitz M; Collier AC; Koup RA; Mellors JW; Connick E; Conway B; Kilby M; Wang L; Whitcomb JM; Hellmann NS; Richman DD
    N Engl J Med; 2002 Aug; 347(6):385-94. PubMed ID: 12167680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa.
    Barth RE; Wensing AM; Tempelman HA; Moraba R; Schuurman R; Hoepelman AI
    AIDS; 2008 Oct; 22(16):2210-2. PubMed ID: 18832885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland.
    von Wyl V; Yerly S; Bürgisser P; Klimkait T; Battegay M; Bernasconi E; Cavassini M; Furrer H; Hirschel B; Vernazza PL; Francioli P; Bonhoeffer S; Ledergerber B; Günthard HF;
    Clin Infect Dis; 2009 Apr; 48(7):979-87. PubMed ID: 19228107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France.
    Chaix ML; Descamps D; Wirden M; Bocket L; Delaugerre C; Tamalet C; Schneider V; Izopet J; Masquelier B; Rouzioux C; Meyer L; Costagliola D; ; ;
    AIDS; 2009 Mar; 23(6):717-24. PubMed ID: 19279445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emergence and epidemiology of resistance in the nucleoside-experienced HIV-infected population.
    Pillay D
    Antivir Ther; 2001; 6 Suppl 3():15-24. PubMed ID: 11678470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV and AIDS: where is the epidemic going?
    Mertens TE; Low-Beer D
    Bull World Health Organ; 1996; 74(2):121-9. PubMed ID: 8706227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary HIV-1 resistance in recently and chronically infected individuals of the Italian Cohort Naive for Antiretrovirals.
    Violin M; Forbici F; Cozzi-Lepri A; Velleca R; Bertoli A; Riva C; Giannella S; Manconi PE; Lazzarin A; Pasquinucci S; Tacconi L; Carnevale G; Mazzotta F; Bonazzi L; Montroni M; Chirianni A; Capobianchi M; Ippolito G; Moroni M; Perno CF; D'Arminio-Monforte A;
    J Biol Regul Homeost Agents; 2002; 16(1):37-43. PubMed ID: 12003172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
    Cuzin L; Allavena C; Morlat P; Dellamonica P
    AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.